Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock
2026-10-05 20:20
•David Jagielski, Cpa •The Motley Fool
••••• ••• Axe Cap view
Eli Lilly’s GLP-1 Boom Is Priced In—Is It Time to Step Back?
Eli Lilly’s rapid rise on GLP-1 drugs faces growing risks amid stiff competition and lofty valuations.
Eli Lilly has been a standout performer, with its GLP-1 drugs like Mounjaro driving a phenomenal 400% gain over five years. The catch? The stock now trades at around 40 times trailing earnings—a stretch that assumes continued sky-high growth. New entrants like Pfizer and Viking Therapeutics are targeting this hot market segment, threatening Lilly’s dominance and growth pace. For South African investors, the key takeaway is cautious—not because you can buy Lilly easily on the JSE, but because a weaker USD/ZAR often reflects global risk vibes. If Lilly stumbles, the rand might feel pressure amid broader emerging market fund flows. Better to avoid chasing what may be a peak valuation, especially when local banks like Standard Bank and FirstRand offer steadier earnings and cheaper multiples. This isn’t to say Lilly’s story is dead; innovation is ongoing. But betting on another 40x growth stretch looks precarious. this is just our opinion and not financial advice
Avoid buying Eli Lilly at these levels. Instead, consider trimming exposure to high-growth global tech and pharma proxies, favoring more stable JSE financial stocks.
- USD/ZAR
- Standard Bank
- FirstRand
- GLP-1 competition reduces Eli Lilly’s growth
- USD/ZAR volatility affects emerging market sentiment
7/10
Eli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations.
Our take is based on reporting first published by The Motley Fool.